CLOVIS ONCOLOGY Forum: Community User: Maroni

sieht doch gut aus...ach ja...ich darf nicht mehr schreiben ;))

Das Zick Zack ist wie gestern.. Na dann der Schluss bitte auch wieder so xD

riesiges Potential mMn - vom CHART her,)

Sieht nicht verkehrt aus auf dem ersten Blick

Keep on rollin....

Where Does Wall Street See the Stock Going? Research firms on the Street have price targets on the name ranging from $21 to $50 with a standard deviation of $10.54. The consensus target from the 6 analysts providing projections currently stands at $33.5. The mean target was last revised on 2016-02-29. These are short term projections for the next 12 months.

Nachbörslich nochmal +5 ct Morgen 15:30 Uhr geht's weiter

Ganz interessant die Zusammenfassung: Clovis Oncology Inc (NASDAQ:CLVS) After being trading in a bearish tone since December the stock appears to making a comeback in favor of the bulls. Clovis Oncology Inc (NASDAQ:CLVS) caught my attention today. The signal to buy was given when the previous day high was taken out. This breakout suggests a possible move to $26. The stock showed a lot of strength and I expect to see another round of buying. On the technical side, the chart looks very good here. CLVS call options were also very active today.

Stifel Nicolaus reissued their buy rating on shares ofClovis Oncology Inc (NASDAQ:CLVS) in a report published on Friday, MarketBeat.comreports. They currently have a $30.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $45.00.

JPMorgan Chase & Co. reiterated their buy rating on shares of Clovis Oncology Inc (NASDAQ:CLVS)in a research note released on Friday morning,Analyst Ratings.Net reports. The brokerage currently has a $42.00 price objective on the biopharmaceutical company’s stock.

Naja Bericht vom Montag.. Lächerlich xD Die anderen Werten mit Buy und 40 USD

Clovis Oncology Inc (NASDAQ:CLVS) had its price target decreased by Goldman Sachs from $23.00 to $19.00 in a report published on Monday,StockTargetPrices.com reports. Shares of Clovis Oncology (NASDAQ:CLVS) opened at 18.00 on Monday. Clovis Oncology has a 12 month low of $17.17 and a 12 month high of $116.75. The firm’s market capitalization is $689.76 million. The stock has a 50 day moving average price of $22.47 and a 200 day moving average price of $60.48. A number of hedge funds and institutional investors recently added to or reduced their stakes in CLVS. Vident Investment Advisory LLC boosted its position in Clovis Oncology by 55.2% in the fourth quarter. Vident Investment Advisory LLC now owns 42,347 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 15,062 shares in the last quarter. Credit Suisse AG boosted its position in Clovis Oncology by 19.3% in the fourth quarter. Credit Suisse AG now owns 125,000 shares of the biopharmaceutical company’s stock valued at $4,375,000 after buying an additional 20,219 shares in the last quarter. Redmile Group LLC boosted its position in Clovis Oncology by 87.5% in the fourth quarter. Redmile Group LLC now owns 1,795,936 shares of the biopharmaceutical company’s stock valued at $62,858,000 after buying an additional 838,302 shares in the last quarter. Palo Alto Investors LLC boosted its position in Clovis Oncology by 14.1% in the fourth quarter. Palo Alto Investors LLC now owns 3,547,719 shares of the biopharmaceutical company’s stock valued at $124,170,000 after buying an additional 438,911 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Clovis Oncology by 294.2% in the fourth quarter. Millennium Management LLC now owns 1,173,873 shares of the biopharmaceutical company’s stock valued at $41,086,000 after buying an additional 876,068 shares in the last quarter. CLVS has been the subject of a number of other reports. Mizuho reduced their target price on shares of Clovis Oncology from $35.00 to $23.00 and set a neutral rating for the company in a research note on Monday, January 25th. JPMorgan Chase & Co. upped their target price on shares of Clovis Oncology from $103.00 to $110.00 and gave the stock an overweight rating in a research note on Friday, November 6th. Vetrraised shares of Clovis Oncology from a hold rating to a strong-buy rating and set a $54.87 target price for the company in a research note on Monday, November 16th. WallachBeth Capital lowered shares of Clovis Oncology from a buy rating to a hold rating and reduced their target price for the stock from $135.00 to $30.00 in a research note on Tuesday, November 17th. Finally,Zacks Investment Research lowered shares of Clovis Oncology from a hold rating to a sell rating in a research note on Friday, December 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $40.89. Clovis Oncology, Inc (NASDAQ:CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib.

sieht chartmässig auf jedem Fall gut aus auch wenn sie nochnal etwas zurückkommt

Wenn die 19,7x gepackt werden ist der nächste technische Widerstand bei 21,6x.. Und dann BAM!

Es hat sich also gelohnt! http://250kb.de/u/160302/j/rg2pRlILhsAm.jpg

Oh mein Gott... Anschnallen!!